Jamile Shammo, MD, FASCP, FACP

Experts discuss treatment options for a 70-year-old woman with low-risk MDS, emphasizing the need for more clinical trial data and real-world evidence.

Clinical Scenario A: 77-year-old male with newly diagnosed LR-MDS

Experts debate the optimal dose escalation strategy for Luspatercept in treating low-risk MDS, emphasizing patient-centric approaches and long-term outcomes.

Experts debate the efficacy of luspatercept versus erythropoietin in treating low-risk MDS, emphasizing individualized patient care and emerging therapies.

Experts debate the optimal timing for initiating treatment in low-risk MDS, emphasizing early intervention to enhance patient quality of life.

Explore the promising long-term outcomes of the IMERG trial, highlighting Emtresat's efficacy and safety for lower-risk MDS patients.

Explore real-world outcomes of hemoglobin treatment in low-risk MDS patients, comparing luspatercept and ESA therapies in a recent study.

Explore real-world outcomes of Luspatercept and second-line ESAs in treating low-risk MDS, revealing promising response rates and treatment insights.

Explore real-world outcomes of Luspatercept and second-line ESAs in treating low-risk MDS, revealing promising response rates and treatment insights.

FACE-OFF: Low-Risk MDS ASH 2025

FACE-OFF: Low-Risk MDS ASH 2025